Aptus Biotech SL, Avda. Cardenal Herrera Oria 298, 28035 Madrid, Spain.
Unidad de Investigación Neurovascular, Departamento de Farmacología y Toxicología, Facultad de Medicina, Instituto Universitario de Investigación en Neuroquímica, Universidad Complutense de Madrid, 28040 Madrid, Spain; Instituto de Investigación Hospital 12 de Octubre (i+12), 28041 Madrid, Spain.
Mol Ther. 2018 Aug 1;26(8):2047-2059. doi: 10.1016/j.ymthe.2018.05.019. Epub 2018 Jun 15.
Since Toll-like receptor 4 (TLR4) mediates brain damage after stroke, development of TLR4 antagonists is a promising therapeutic strategy for this disease. Our aim was to generate TLR4-blocking DNA aptamers to be used for stroke treatment. From a random oligonucleotide pool, we identified two aptamers (ApTLR#1R, ApTLR#4F) with high affinity for human TLR4 by systematic evolution of ligands by exponential enrichment (SELEX). Optimized truncated forms (ApTLR#1RT, ApTLR#4FT) were obtained. Our data demonstrate specific binding of both aptamers to human TLR4 as well as a TLR4 antagonistic effect. ApTLR#4F and ApTLR#4FT showed a long-lasting protective effect against brain injury induced by middle cerebral artery occlusion (MCAO), an effect that was absent in TLR4-deficient mice. Similar effects were obtained in other MCAO models, including in rat. Additionally, efficacy of ApTLR#4FT in a model of brain ischemia-reperfusion in rat supports the use of this aptamer in patients undergoing artery recanalization induced by pharmacological or mechanical interventions. The absence of major toxicology aspects and the good safety profile of the aptamers further encourage their future clinical positioning for stroke therapy and possibly other diseases in which TLR4 plays a deleterious role.
由于 Toll 样受体 4(TLR4)介导中风后的脑损伤,因此开发 TLR4 拮抗剂是治疗这种疾病的一种很有前途的治疗策略。我们的目的是生成 TLR4 阻断 DNA 适体,用于中风治疗。通过指数富集的配体系统进化(SELEX),从随机寡核苷酸池中鉴定出两种对人 TLR4 具有高亲和力的适体(ApTLR#1R,ApTLR#4F)。得到了优化的截断形式(ApTLR#1RT,ApTLR#4FT)。我们的数据表明,两种适体都能特异性结合人 TLR4,并具有 TLR4 拮抗作用。ApTLR#4F 和 ApTLR#4FT 对大脑中动脉闭塞(MCAO)引起的脑损伤具有持久的保护作用,而 TLR4 缺陷型小鼠则没有这种作用。在其他 MCAO 模型中也获得了类似的效果,包括在大鼠中。此外,ApTLR#4FT 在大鼠脑缺血再灌注模型中的疗效支持在接受药物或机械干预引起的动脉再通的患者中使用这种适体。该适体没有出现主要的毒理学问题,并且具有良好的安全性,这进一步鼓励其未来在中风治疗以及 TLR4 发挥有害作用的其他疾病中的临床定位。